Bellicum Pharmaceuticals IncOTC Pink - Current Information:BLCM
- LAST PRICE0.3201
- TODAY'S CHANGE (%)-0.0163 (-4.8511%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.3591 / 0.3364
- Day Range
- 52 Week Range
- Volume4,426
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLCM |
|---|---|---|
| 10:01 ET | 100 | 0.359075 |
| 01:01 ET | 100 | 0.3201 |
| 02:40 ET | 4000 | 0.3201 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bellicum Pharmaceuticals Inc | 3.2M | -0.3x | --- |
Baudax Bio Inc | 2.8M | 0.0x | --- |
Intelligent Bio Solutions Inc | 2.6M | -0.1x | --- |
InMed Pharmaceuticals Inc | 2.4M | 0.0x | --- |
Cannabis Global, Inc. | 625.6K | 0.0x | --- |
ABVC Biopharma Inc | 4.0M | -0.3x | --- |
Company Information
Bellicum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. It has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.
Contact Information
- Headquarters
- 3730 Kirby Drive, Suite 1200HOUSTON, TX, United States 77098
- Phone
- 832-384-1100
- Fax
- 302-655-5049
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2M |
|---|---|
Revenue (TTM) | $1.5M |
Shares Outstanding | 9.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.35 |
EPS | $-0.93 |
Book Value | $2.33 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,003.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
